Informativa sui cookie

Utilizziamo i cookie per raccogliere e analizzare le informazioni sulle prestazioni e l'utilizzo del sito e per verificare la riuscita della navigazione in tutto il sito. Facendo clic sul pulsante “OK” a destra o su qualsiasi contenuto del sito, accettate la collocazione dei cookie sul vostro computer. Per ulteriori informazioni, consultare la nostra Informativa sulla privacy. 

 
Sedi
 
SITI WEB
  • United States (English)
  • International (English)
  • Cinese (中文)
  • Francese (Français)
  • Tedesco (Deutsch)
  • Italiano
  • Giapponese (日本語)
  • Russo (Русский)
  • Whole Blood Technologies
 

YesNo
  • Relazioni con gli investitori
  • LOGIN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTRA
  • Home
  • Prodotti
     
    Prodotti internazionaliView U. S. Products View U.S. Whole Blood Technologies
    Dispositivi
    Dispositivi chirurgici e diagnostici
    • Cell Saver 5+
    • Cell Saver Elite
    • SmartSuction Harmony
    • TEG
    Dispositivi per i centri per la raccolta del plasma e del sangue
    • ACP 215
    • MCS+
    • PCS 2
    Software
    Software per centri trasfusionali
    • Donor Doc
    • EdgeBlood
    • eDonor
    • eLynx
    • Hemasphere
    Software per ospedali
    • BloodTrack
    • EdgeCell
    • EdgeLab
    • EdgeTrack
    Software per i centri per la raccolta del plasma
    • DonorDoc

    • EdgeBlood
    • eDonor

    • eLynx

    Servizi
    Servizi software
    • Panoramica dei servizi software
    • Assistenza ai clienti
    • Servizi di formazione
    • Servizi di implementazione
    • Assistenza tecnica
    • Servizi di convalida
     
  • Soluzioni
     
    Soluzioni per la gestione del sangue
    • Soluzioni per centri trasfusionali
    • Soluzioni per gli ospedali
    • Soluzioni per centri per la raccolta del plasma
     
  • Centro di apprendimento
     
    Leadership di pensiero e ricerca
    • White paper e revisioni cliniche (in inglese)
    • Liste di riferimenti (in inglese)
    • Abstract (in inglese)
    Formazione
    • Presentazione
    Service Training
       
    • Informazioni su Haemonetics
       
      Presentazione della società
      • Informazioni generali
      • Momenti storici
      • Team dirigenziale
      • Sedi degli uffici
      Relazioni con gli investitori
      • Relazioni con gli investitori - Pagina iniziale
      • Informazioni sulle azioni
      • Utili
      • Previsioni e linee guida
      Notizie ed eventi
      • Notizie
      • Eventi
      Opportunità di carriera
      • Panoramica delle opportunità
      Grants 
         
      • Assistenza clienti

      YesNo
      • Pagina iniziale
      • Centro di apprendimento
      • Leadership di pensiero e ricerca
      • White paper e revisioni cliniche (in inglese)
      • Contattateci
      • Print
      • Share

      White paper e revisioni cliniche (in inglese)

      • TEG opens up new horizons in Interventional Cardiology for tailored Anti-Platelet Treatment

        White Paper Dr. João Dias and Dr. Jan Hartmann

        The new European guidelines for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) recommend antiplatelet therapy (APT) de-escalation guided by platelet function tests (PFT). Thromboelastography (TEG) is a PFT for personalized assessment of APT treatment and responsiveness. This paper provides an overview of the scientific and clinical evidence supporting the use of the new point-of-care TEG®6s system in interventional cardiology for personalized antiplatelet treatment.
        Document coming soon!

      • Whitepaper_COL-PP-000225-IE
      • Plateletapheresis: indicators of product quality

        White Paper João Dias, PhD and Mark Popovsky, M.D.

        This white paper provides an overview of the key in vitro and in vivo quality matrixes for plateletapheresis products and discusses the reported differences of these indicators between different technologies. View document

      • Key technologies for improving Patient Blood Management

        White Paper João Dias, PhD and Mark Popovsky, M.D.

        This white paper provides an overview of the key aspects of patient blood management (PBM) and  discusses the role of products and technologies such as viscoelastic hemostatic assays (VHA), cell salvage devices and Point of Care Electronic Blood Management (PoCEBM) systems in enabling and improving PBM. View document

      • FOCUS Trial - Functional outcomes in cardiovascular patients undergoing surgical repair of hip fracture

        Clinical Review: N Engl J Med 2011; 365:2453-62

        Conclusion: A liberal transfusion strategy, as compared with a restrictive strategy, did not reduce rates of death or inability to walk independently on 60-day follow-up or reduce in-hospital morbidity in elderly patients at high cardiovascular risk.
        View document
      • Red Cell Salvage: Current Status

        White Paper by M. Popovsky

        Summary: Intraoperative red cell salvage has been shown to reduce the risks of allogenic transfusion: Its utilization reduces the need for allogeneic RBC transfusion. The RBC are functionally superior to stored RBC. When utilized appropriately, the economics are favorable.
        View document
      • Anemia and the Perioperative Patient

        White Paper by M. Popovsky, M.D., R. Thurer, M.D., P. Parce, RN

        Excerpt: Anemia is a remarkably prevalent condition. Forty percent of patients presenting with hip fracture and 38% of acutely admitted geriatric patients have anemia (5). Studies of critically ill patients found that 77% experience anemia in the ICU. Sixty three percent of these patients had hemoglobin values less than 12 g/dL and 29% less than 10g/dL. View document View reference list
      • Blood Management: State of the Art
        The Use of Red Blood Cells and Fresh Frozen Plasma

        White Paper by M. Popovsky, M.D., R. Thurer, M.D., P. Parce, RN

        Excerpt: Blood transfusion is an integral part of medical and surgical practice, and its safety is now assumed. Although the transmission of virus-borne diseases – such as HIV and hepatitis – by blood transfusion are extraordinarily rare events, blood should be viewed as a potent drug that entails significant risk.
        View document View reference list
      • The Pros and Cons of Preoperative Autologous Blood Donation

        White Paper by Mark A. Popovsky, M.D., Robert L. Thurer, M.D.

        Preoperative autologous blood donation (PABD) was once a powerful tool to decrease the risk of transfusion-transmitted disease related to allogeneic blood. With the development of effective viral screening tests and the recognition of the many disadvantages of stored blood, the need for and appropriateness of PABD has greatly diminished. There are now better and safer alternatives. The advantages and disadvantages of PABD are discussed in this review. View document
      • Contattateci
      • Termini d'uso
      • Qualità
      • Informativa sulla privacy
      • Mappa del sito

      © 2011-2019 Haemonetics Corporation